US Pharma MarketingDimerix acquisition of DMX-652 bolsters kidney disease development
Dimerix acquisition of DMX-652 bolsters kidney disease development is a pharma and life sciences industry update from Pharmaceutical Technology. The story may affect commercial strategy, market access planning, stakeholder engagement, competitive positioning, and near-term monitoring for pharmaceutical and biotech teams.
Dimerix adds DMX-652, a Phase II-ready AKI asset, strengthening its kidney disease pipeline beyond focal segmental glomerulosclerosis (FSGS).
Source: Pharmaceutical Technology